Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):287-293
Until now, mutational resistance to fluoroquinolones (FQs) that represent a second-line treatment option for chlamydial infections after macrolides and tetrxacyclines has not been described in clinical isolates of C. trachomatis. However, a …